GENSCRIPT BIOTECH CORPORATIONGENSCRIPT BIOTECH CORPORATIONGENSCRIPT BIOTECH CORPORATION

GENSCRIPT BIOTECH CORPORATION

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪23.04 B‬HKD
−0.66HKD
‪−747.48 M‬HKD
‪6.57 B‬HKD
‪1.03 B‬
Beta (1Y)
0.93
Employees (FY)
‪6.94 K‬
Change (1Y)
+724 +11.65%
Revenue / Employee (1Y)
‪121.31 K‬HKD
Net income / Employee (1Y)
‪−13.80 K‬HKD

About GENSCRIPT BIOTECH CORPORATION


CEO
Weihui Shao
Headquarters
Nanjing
Founded
2002
FIGI
BBG009XY51J1
Genscript Biotech Corp. is a holding company, which engages in the manufacture and sale of life sciences research products and services. It operates through the following segments: Bio-science Services and Products; Precision Immune-cell Therapy; and Industrial Synthetic Biology Products. The Bio-science Services and Products segment includes life sciences research services, life sciences research catalogue products, and preclinical drug development services. The Precision Immune-cell Therapy segment discovers and develops therapies for the treatment of liquid tumour through optimised CAR structures and the development of bispecific CAR-T therapies. The Industrial Synthetic Biology Products segment comprises of the construction of non-pathogenic microbial strains and industrial enzyme development and production. The company was founded by Fang Liang Zhang, Lu Quan Wang, and Ye Wang in 2002 and is headquartered in Nanjing, China.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 1548 is 10.88 HKD — it has decreased by −6.85% in the past 24 hours. Watch GENSCRIPT BIOTECH CORPORATION stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange GENSCRIPT BIOTECH CORPORATION stocks are traded under the ticker 1548.
1548 stock has fallen by −8.57% compared to the previous week, the month change is a −19.29% fall, over the last year GENSCRIPT BIOTECH CORPORATION has showed a −54.95% decrease.
We've gathered analysts' opinions on GENSCRIPT BIOTECH CORPORATION future price: according to them, 1548 price has a max estimate of 29.06 HKD and a min estimate of 16.00 HKD. Watch 1548 chart and read a more detailed GENSCRIPT BIOTECH CORPORATION stock forecast: see what analysts think of GENSCRIPT BIOTECH CORPORATION and suggest that you do with its stocks.
1548 reached its all-time high on Jul 20, 2021 with the price of 43.40 HKD, and its all-time low was 1.08 HKD and was reached on May 27, 2016. View more price dynamics on 1548 chart.
See other stocks reaching their highest and lowest prices.
1548 stock is 9.29% volatile and has beta coefficient of 0.93. Track GENSCRIPT BIOTECH CORPORATION stock price on the chart and check out the list of the most volatile stocks — is GENSCRIPT BIOTECH CORPORATION there?
Today GENSCRIPT BIOTECH CORPORATION has the market capitalization of ‪22.85 B‬, it has decreased by −3.26% over the last week.
Yes, you can track GENSCRIPT BIOTECH CORPORATION financials in yearly and quarterly reports right on TradingView.
GENSCRIPT BIOTECH CORPORATION is going to release the next earnings report on Mar 21, 2025. Keep track of upcoming events with our Earnings Calendar.
1548 earnings for the last half-year are −0.65 HKD per share, whereas the estimation was −0.08 HKD, resulting in a −727.00% surprise. The estimated earnings for the next half-year are −0.08 HKD per share. See more details about GENSCRIPT BIOTECH CORPORATION earnings.
GENSCRIPT BIOTECH CORPORATION revenue for the last half-year amounts to ‪4.38 B‬ HKD, despite the estimated figure of ‪4.28 B‬ HKD. In the next half-year revenue is expected to reach ‪5.03 B‬ HKD.
1548 net income for the last half-year is ‪−1.37 B‬ HKD, while the previous report showed ‪−14.83 M‬ HKD of net income which accounts for ‪−9.14 K‬% change. Track more GENSCRIPT BIOTECH CORPORATION financial stats to get the full picture.
No, 1548 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 9, 2024, the company has ‪6.94 K‬ employees. See our rating of the largest employees — is GENSCRIPT BIOTECH CORPORATION on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GENSCRIPT BIOTECH CORPORATION EBITDA is ‪−1.42 B‬ HKD, and current EBITDA margin is −37.66%. See more stats in GENSCRIPT BIOTECH CORPORATION financial statements.
Like other stocks, 1548 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENSCRIPT BIOTECH CORPORATION stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GENSCRIPT BIOTECH CORPORATION technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GENSCRIPT BIOTECH CORPORATION stock shows the sell signal. See more of GENSCRIPT BIOTECH CORPORATION technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.